2008 2013 Access Safety 
Cannabis Law Report
JULY 20, 2021
The creation of this standalone cannabis department is part of a larger effort to improve access to licensure, simplify regulatory oversight and support California businesses. Salama was Assistant Branch Chief of the California Department of Public Health’s Manufactured Cannabis Safety Branch. Chief Deputy Director – Rasha Salama.
Cannabis Law Report
FEBRUARY 1, 2022
Invert believes in making the world of carbon credits accessible to everyone, big or small. Rade Kovacevic has been a lifelong entrepreneur, founding Cerium Media in 1998, the Medical Cannabis Centre of Guelph in 2006, MedCannAccess in 2013 and The Greater Return in 2021. About Mark Zekulin. About Rade Kovacevic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 7, 2019
Our growing relationship with Folium Biosciences provides Australis and our brands access to the true global leader in the CBD space,” said Scott Dowty, CEO of Australis. “We Folium would be unable to meet sales commitments if they could not get access to hemp stock.
Cannabis Law Report
MAY 26, 2022
was published in the Journal of Safety Research and made available online on May 18. Journal of Safety Research. The objective of the current study was to assess the ease of access to marijuana by underage patrons at recreational marijuana outlets in California, where recreational marijuana was legalized in 2016.
Cannabis Law Report
JULY 31, 2019
3] The CSA established five schedules of controlled substances, with Schedule I substances defined as those which have a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. [4] Health and Safety Code § 11362.5. [7] 812(b)(1). [5]
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. 2018 ; Frankhauser 2008 ). The review, however, did not cover patient access to medicinal cannabis.
Cannabis Law Report
APRIL 8, 2022
The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer. Rick Doblin, Ph.D.,
Expert insights. Personalized for you.
105 
Let's personalize your content